Company Overview and News

 
Corvus Gold Continues to Expand Deposit West, Drill Results Include 33.5 Metres @ 2.2 g/t Gold, Mother Lode Project, Nevada

3h globenewswire
VANCOUVER, British Columbia, April 25, 2018 (GLOBE NEWSWIRE) -- Corvus Gold Inc. (“Corvus” or the “Company”) - (TSX:KOR) (OTCQX:CORVF) announces it has received results from three stepout holes in the southwest extension of the Mother Lode deposit (Figure 1) highlighted by hole ML18-053 which returned 33.5m @ 2.2 g/t gold including 19.8m @ 3.3 g/t gold. Assay results returned encouraging intercepts showing continued expansion of the deposit which is nearly all oxide to the bottom of the holes (Table 1).
Upvote Downvote

 
CORVF / Corvus Gold, Inc. FORM 10-Q (Quarterly Report)

2018-04-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
Upvote Downvote

 
CORVF / Corvus Gold, Inc. FORM 8-K (Current Report)

2018-04-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
Upvote Downvote

 
CORVF / Corvus Gold, Inc. FORM 8-K (Current Report)

2018-03-22 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
Upvote Downvote

 
CORVF / Corvus Gold, Inc. FORM 8-K (Current Report)

2018-03-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
Upvote Downvote

 
CORVF / Corvus Gold, Inc. FORM 8-K (Current Report)

2018-02-22 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 22, 2018   Corvus Gold Inc. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada 000-55447 98-0668473 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
Upvote Downvote

 
CORVF / Corvus Gold, Inc. FORM 8-K (Current Report)

2018-02-21 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 14, 2018   Corvus Gold Inc. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada 000-55447 98-0668473 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
Upvote Downvote

 
Mother Of Diminishing Returns

2018-02-20 seekingalpha
Recently completing Phase I of its drill program at the Mother Lode project in Nevada, Corvus Gold has made great strides in its stated intention of confirming and expanding historic mineralization estimates. However, a closer analysis of its results casts doubt on the project's feasibility.
Upvote Downvote

 
CORVF / Corvus Gold, Inc. FORM 8-K (Current Report)

2018-02-02 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 1, 2018   Corvus Gold Inc. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada 000-55447 98-0668473 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
Upvote Downvote

 
CORVF / Corvus Gold, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-30 fintel.io
Corvus Gold, Inc. (OTC:CORVF) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 110,000 shares. Largest shareholders include First Midwest Bank Trust Division.
Upvote Downvote

 
CORVF / Corvus Gold, Inc. / TOCQUEVILLE ASSET MANAGEMENT L.P. - NONE (Passive Investment)

2018-01-30 sec.gov
Schedule 13G   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. n/a )*   Corvus Gold Inc.  (Name of Issuer)   Common Shares, no par value (Title of Class of Securities)   221013105 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:        x  Rule 13d-1(b)        o  Rul
Upvote Downvote

 
CORVF / Corvus Gold, Inc. / TOCQUEVILLE ASSET MANAGEMENT L.P. - NONE (Passive Investment)

2018-01-30 sec.gov
Schedule 13G   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. n/a )*   Corvus Gold Inc.  (Name of Issuer)   Common Shares, no par value (Title of Class of Securities)   221013105 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:        x  Rule 13d-1(b)        o  Rul
Upvote Downvote

 
CORVF / Corvus Gold, Inc. FORM 10-Q (Quarterly Report)

2018-01-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
Upvote Downvote

 
CORVF / Corvus Gold, Inc. FORM 8-K (Current Report)

2018-01-11 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 10, 2018   Corvus Gold Inc. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada 000-55447 98-0668473 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
Upvote Downvote

2
Resource Sector Digest: Oh No, Gold Is Swooning!

2017-12-15 seekingalpha
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 221013105